{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:34:05Z","timestamp":1793644445846,"version":"4.5.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81991491"],"award-info":[{"award-number":["81991491"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2019RU022"],"award-info":[{"award-number":["2019RU022"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","award":["20720220006"],"award-info":[{"award-number":["20720220006"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","award":["20720220004"],"award-info":[{"award-number":["20720220004"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03423-w","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T03:04:03Z","timestamp":1748574243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity and cellular response of a herpes zoster virus gEgI fusion protein adjuvanted with CpG-emulsion in mice"],"prefix":"10.1186","volume":"23","author":[{"given":"Sibo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueting","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"3423_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrmicro3215","volume":"12","author":"L Zerboni","year":"2014","unstructured":"Zerboni L, Sen N, Oliver SL, Arvin AM. Molecular mechanisms of varicella Zoster virus pathogenesis. Nat Rev Microbiol. 2014;12:197\u2013210.","journal-title":"Nat Rev Microbiol"},{"key":"3423_CR2","doi-asserted-by":"crossref","unstructured":"A AM: Varicella-Zoster virus. CLINMICROBIOLREV 1996:361\u201381.","DOI":"10.1128\/CMR.9.3.361"},{"key":"3423_CR3","doi-asserted-by":"crossref","unstructured":"H. GD: Varicella-zoster virus DNA in human sensory ganglia. Nature 1983, 306.","DOI":"10.1038\/306478a0"},{"key":"3423_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1084\/jem.20040634","volume":"200","author":"CC Ku","year":"2004","unstructured":"Ku CC, Zerboni L, Ito H, Graham BS, Wallace M, Arvin AM. Varicella-zoster virus transfer to skin by T cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med. 2004;200:917\u201325.","journal-title":"J Exp Med"},{"key":"3423_CR5","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1093\/infdis\/jiy403","volume":"218","author":"KJ Laing","year":"2018","unstructured":"Laing KJ, Ouwendijk WJD, Koelle DM, Verjans G. Immunobiology of Varicella-Zoster virus infection. J Infect Dis. 2018;218:S68\u201374.","journal-title":"J Infect Dis"},{"key":"3423_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.coviro.2013.04.004","volume":"3","author":"WJ Ouwendijk","year":"2013","unstructured":"Ouwendijk WJ, Laing KJ, Verjans GM, Koelle DM. T-cell immunity to human alphaherpesviruses. Curr Opin Virol. 2013;3:452\u201360.","journal-title":"Curr Opin Virol"},{"key":"3423_CR7","doi-asserted-by":"crossref","unstructured":"Patil A, Goldust M, Wollina U. Herpes Zoster: A review of clinical manifestations and management. Viruses 2022, 14.","DOI":"10.3390\/v14020192"},{"key":"3423_CR8","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","volume":"1","author":"AA Gershon","year":"2015","unstructured":"Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Grose C, Hambleton S, Kennedy PG, Oxman MN, et al. Varicella Zoster virus infection. Nat Rev Dis Primers. 2015;1:15016.","journal-title":"Nat Rev Dis Primers"},{"key":"3423_CR9","doi-asserted-by":"crossref","unstructured":"Tommasi C, Breuer J. The biology of Varicella-Zoster virus replication in the skin. Viruses 2022, 14.","DOI":"10.3390\/v14050982"},{"key":"3423_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1080\/14787210.2021.1917992","volume":"19","author":"K Shiraki","year":"2021","unstructured":"Shiraki K, Takemoto M, Daikoku T. Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment. Expert Rev Anti Infect Ther. 2021;19:1415\u201325.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3423_CR11","doi-asserted-by":"crossref","unstructured":"Takahashi M, Okuno TOY, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974.","DOI":"10.1016\/S0140-6736(74)90144-5"},{"key":"3423_CR12","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","volume":"224","author":"R Harbecke","year":"2021","unstructured":"Harbecke R, Cohen JI, Oxman MN. Herpes Zoster vaccines. J Infect Dis. 2021;224:S429\u201342.","journal-title":"J Infect Dis"},{"key":"3423_CR13","doi-asserted-by":"crossref","unstructured":"Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen S. J.: Herpes Zoster vaccine in older adults and the risk of subsequent herpes Zoster disease. JAMA 2011, 305.","DOI":"10.1001\/jama.2010.1983"},{"key":"3423_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, et al. Efficacy of the herpes Zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019\u201332.","journal-title":"N Engl J Med"},{"key":"3423_CR15","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, et al. Efficacy of an adjuvanted herpes Zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087\u201396.","journal-title":"N Engl J Med"},{"key":"3423_CR16","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/cid\/ciab629","volume":"74","author":"C Boutry","year":"2022","unstructured":"Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, Beytout J, Caso C, Cheng HS, Cheong HJ, et al. The adjuvanted Recombinant Zoster vaccine confers Long-Term protection against herpes Zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022;74:1459\u201367.","journal-title":"Clin Infect Dis"},{"key":"3423_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","volume":"2","author":"M Coccia","year":"2017","unstructured":"Coccia M, Collignon C, Herve C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNgamma response promoting vaccine immunogenicity. NPJ Vaccines. 2017;2:25.","journal-title":"NPJ Vaccines"},{"key":"3423_CR18","doi-asserted-by":"crossref","unstructured":"Tricco AC, Zarin W, Cardoso R, Veroniki A-A, Khan PA, Nincic V, Ghassemi M, Warren R, Sharpe JP, Page AV, Straus SE. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. Bmj. 2018.","DOI":"10.1136\/bmj.k4029"},{"key":"3423_CR19","doi-asserted-by":"crossref","unstructured":"Cheng X, Liu S, Sun J, Liu L, Ma X, Li J, Fan B, Yang C, Zhao Y, Liu S et al. A synergistic lipid nanoparticle encapsulating mRNA shingles vaccine induces potent immune responses and protects Guinea pigs from viral challenges. Adv Mater 2023, 36.","DOI":"10.1002\/adma.202310886"},{"key":"3423_CR20","doi-asserted-by":"crossref","unstructured":"Nam HJ, Hong SJ, Lee A, Kim J, Lee S, Casper C, Carter D, Reed SG, Simeon G, Shin E-C. An adjuvanted Zoster vaccine elicits potent cellular immune responses in mice without QS21. Npj Vaccines 2022, 7.","DOI":"10.1038\/s41541-022-00467-z"},{"key":"3423_CR21","doi-asserted-by":"crossref","unstructured":"Jeong S-K, Ham S-J, Baek S-H, Jung E-J, Jo H-J, Cha H-R, Lee J-M, Ahn BC, Yum JS, Chun E. Lipo-pam\u2122 adjuvanted herpes Zoster vaccine induces potent gE-specific cellular and humoral immune responses. Npj Vaccines 2024, 9.","DOI":"10.1038\/s41541-024-00939-4"},{"key":"3423_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s40588-016-0044-4","volume":"3","author":"SL Oliver","year":"2016","unstructured":"Oliver SL, Yang E, Arvin AM. Varicella-Zoster virus glycoproteins: entry, replication, and pathogenesis. Curr Clin Microbiol Rep. 2016;3:204\u201315.","journal-title":"Curr Clin Microbiol Rep"},{"key":"3423_CR23","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1128\/JVI.02596-10","volume":"85","author":"SL Oliver","year":"2011","unstructured":"Oliver SL, Sommer MH, Reichelt M, Rajamani J, Vlaycheva-Beisheim L, Stamatis S, Cheng J, Jones C, Zehnder J, Arvin AM. Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE\/gI heterodimer formation, gI structure, and virulence in skin cells. J Virol. 2011;85:4095\u2013110.","journal-title":"J Virol"},{"key":"3423_CR24","doi-asserted-by":"publisher","first-page":"13719","DOI":"10.1128\/JVI.02293-13","volume":"87","author":"J Christensen","year":"2013","unstructured":"Christensen J, Steain M, Slobedman B, Abendroth A. Varicella-zoster virus glycoprotein I is essential for spread in dorsal root ganglia and facilitates axonal localization of structural virion components in neuronal cultures. J Virol. 2013;87:13719\u201328.","journal-title":"J Virol"},{"key":"3423_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1128\/JVI.00913-08","volume":"83","author":"B Berarducci","year":"2009","unstructured":"Berarducci B, Rajamani J, Reichelt M, Sommer M, Zerboni L, Arvin AM. Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry. J Virol. 2009;83:228\u201340.","journal-title":"J Virol"},{"key":"3423_CR26","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/infdis\/jiv164","volume":"212","author":"KJ Laing","year":"2015","unstructured":"Laing KJ, Russell RM, Dong L, Schmid DS, Stern M, Magaret A, Haas JG, Johnston C, Wald A, Koelle DM. Zoster vaccination increases the breadth of CD4\u2009+\u2009T cells responsive to varicella Zoster virus. J Infect Dis. 2015;212:1022\u201331.","journal-title":"J Infect Dis"},{"key":"3423_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14760584.2023.2238807","volume":"22","author":"Y Zeng","year":"2023","unstructured":"Zeng Y, Zou F, Xia N, Li S. In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives. Expert Rev Vaccines. 2023;22:681\u201395.","journal-title":"Expert Rev Vaccines"},{"key":"3423_CR28","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","volume":"30","author":"DT O\u2019Hagan","year":"2012","unstructured":"O\u2019Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59\u2013 An innately attractive adjuvant formulation. Vaccine. 2012;30:4341\u20138.","journal-title":"Vaccine"},{"key":"3423_CR29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.cell.2006.02.019","volume":"124","author":"B Pulendran","year":"2006","unstructured":"Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 2006;124:849\u201363.","journal-title":"Cell"},{"key":"3423_CR30","doi-asserted-by":"crossref","unstructured":"Pulendran B, O\u2019Hagan PSA. DT: Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov 2021.","DOI":"10.1038\/s41573-021-00163-y"},{"key":"3423_CR31","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.vaccine.2018.03.067","volume":"36","author":"R Hyer","year":"2018","unstructured":"Hyer R, McGuire DK, Xing B, Jackson S, Janssen R. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults. Vaccine. 2018;36:2604\u201311.","journal-title":"Vaccine"},{"key":"3423_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.vaccine.2022.10.030","volume":"41","author":"J Torales","year":"2023","unstructured":"Torales J, Cuenca-Torres O, Barrios L, Armoa-Garcia L, Estigarribia G, Sanabria G, Lin M-Y, Antonio Estrada J, Estephan L, Cheng H-Y, et al. An evaluation of the safety and immunogenicity of MVC-COV1901: results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled Immunobridging study in Paraguay. Vaccine. 2023;41:109\u201318.","journal-title":"Vaccine"},{"key":"3423_CR33","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.vaccine.2009.12.014","volume":"28","author":"F Roman","year":"2010","unstructured":"Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster J-M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine. 2010;28:1740\u20135.","journal-title":"Vaccine"},{"key":"3423_CR34","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.vaccine.2017.02.057","volume":"35","author":"A Madan","year":"2017","unstructured":"Madan A, Ferguson M, Rheault P, Seiden D, Toma A, Friel D, Soni J, Li P, Innis BL, Schuind A. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: A phase II, observer-blind, randomized, controlled trial. Vaccine. 2017;35:1865\u201372.","journal-title":"Vaccine"},{"key":"3423_CR35","doi-asserted-by":"crossref","unstructured":"Wu Y, Huang X, Yuan L, Wang S, Zhang Y, Xiong H, Chen R, Ma J, Qi R, Nie M. A Recombinant Spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Sci Transl Med 2021, 13.","DOI":"10.1126\/scitranslmed.abg1143"},{"key":"3423_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nri2510","volume":"9","author":"P Marrack","year":"2009","unstructured":"Marrack P, McKee A, Munks M. Towards an Understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9:287\u201393.","journal-title":"Nat Rev Immunol"},{"key":"3423_CR37","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Basturk O, VanWyk H, et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024;30:531\u201342.","journal-title":"Nat Med"},{"key":"3423_CR38","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1086\/533467","volume":"46","author":"CL Cooper","year":"2008","unstructured":"Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-Infected adults achieves Long\u2010Term seroprotection for up to 5 years. Clin Infect Dis. 2008;46:1310\u20134.","journal-title":"Clin Infect Dis"},{"key":"3423_CR39","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1016\/j.vaccine.2011.02.057","volume":"29","author":"C Cheng","year":"2011","unstructured":"Cheng C, Pal S, Bettahi I, Oxford KL, Barry PA, de la Maza LM. Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model. Vaccine. 2011;29:3456\u201364.","journal-title":"Vaccine"},{"key":"3423_CR40","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/infdis\/jix482","volume":"216","author":"K Grupping","year":"2017","unstructured":"Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, Peterson J, Vastiau I, Oostvogels L. Immunogenicity and safety of the HZ\/su adjuvanted herpes Zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes Zoster vaccine. J Infect Dis. 2017;216:1343\u201351.","journal-title":"J Infect Dis"},{"key":"3423_CR41","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/infdis\/jit365","volume":"208","author":"R Chlibek","year":"2013","unstructured":"Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes Zoster in adults\u2009>\u2009=\u200950 years of age. J Infect Dis. 2013;208:1953\u201361.","journal-title":"J Infect Dis"},{"key":"3423_CR42","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","volume":"32","author":"R Chlibek","year":"2014","unstructured":"Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, Plassmann G, Schwarz TF, Ledent E, Heineman TC. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32:1745\u201353.","journal-title":"Vaccine"},{"key":"3423_CR43","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.4161\/hv.24269","volume":"9","author":"H Lal","year":"2013","unstructured":"Lal H, Zahaf T, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella Zoster virus subunit candidate vaccine (HZ\/su): a phase-I, open-label study in Japanese adults. Hum Vaccin Immunother. 2013;9:1425\u20139.","journal-title":"Hum Vaccin Immunother"},{"key":"3423_CR44","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1586\/erv.11.18","volume":"10","author":"G Ragupathi","year":"2011","unstructured":"Ragupathi G, Gardner JR, Livingston PO, Gin DY. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines. 2011;10:463\u201370.","journal-title":"Expert Rev Vaccines"},{"key":"3423_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","volume":"19","author":"J Nikolich-\u017dugich","year":"2017","unstructured":"Nikolich-\u017dugich J. The Twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2017;19:10\u20139.","journal-title":"Nat Immunol"},{"key":"3423_CR46","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/ni.2588","volume":"14","author":"JJ Goronzy","year":"2013","unstructured":"Goronzy JJ, Weyand CM. Understanding Immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14:428\u201336.","journal-title":"Nat Immunol"},{"key":"3423_CR47","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41577-021-00537-8","volume":"21","author":"M Reina-Campos","year":"2021","unstructured":"Reina-Campos M, Scharping NE, Goldrath AW. CD8(+) T cell metabolism in infection and cancer. Nat Rev Immunol. 2021;21:718\u201338.","journal-title":"Nat Rev Immunol"},{"key":"3423_CR48","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1073\/pnas.1500475112","volume":"112","author":"RS Akondy","year":"2015","unstructured":"Akondy RS, Johnson PL, Nakaya HI, Edupuganti S, Mulligan MJ, Lawson B, Miller JD, Pulendran B, Antia R, Ahmed R. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc Natl Acad Sci U S A. 2015;112:3050\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3423_CR49","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","volume":"28","author":"JD Miller","year":"2008","unstructured":"Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, et al. Human effector and memory CD8\u2009+\u2009T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28:710\u201322.","journal-title":"Immunity"},{"key":"3423_CR50","doi-asserted-by":"publisher","first-page":"6957","DOI":"10.1038\/s41467-022-34698-4","volume":"13","author":"KJ Laing","year":"2022","unstructured":"Laing KJ, Ouwendijk WJD, Campbell VL, McClurkan CL, Mortazavi S, Elder Waters M, Krist MP, Tu R, Nguyen N, Basu K, et al. Selective retention of virus-specific tissue-resident T cells in healed skin after recovery from herpes Zoster. Nat Commun. 2022;13:6957.","journal-title":"Nat Commun"},{"key":"3423_CR51","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/ph6050579","volume":"6","author":"T Lai","year":"2013","unstructured":"Lai T, Yang Y, Ng SK. Advances in mammalian cell line development technologies for Recombinant protein production. Pharmaceuticals (Basel). 2013;6:579\u2013603.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3423_CR52","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00253-011-3758-5","volume":"93","author":"JY Kim","year":"2012","unstructured":"Kim JY, Kim YG, Lee GM. CHO cells in biotechnology for production of Recombinant proteins: current state and further potential. Appl Microbiol Biotechnol. 2012;93:917\u201330.","journal-title":"Appl Microbiol Biotechnol"},{"key":"3423_CR53","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.1128\/JVI.00392-12","volume":"86","author":"E Clo","year":"2012","unstructured":"Clo E, Kracun SK, Nudelman AS, Jensen KJ, Liljeqvist JA, Olofsson S, Bergstrom T, Blixt O. Characterization of the viral O-glycopeptidome: a novel tool of relevance for vaccine design and serodiagnosis. J Virol. 2012;86:6268\u201378.","journal-title":"J Virol"},{"key":"3423_CR54","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10719-012-9465-3","volume":"30","author":"I D\u2019Arrigo","year":"2013","unstructured":"D\u2019Arrigo I, Clo E, Bergstrom T, Olofsson S, Blixt O. Diverse IgG serum response to novel glycopeptide epitopes detected within immunodominant stretches of Epstein-Barr virus glycoprotein 350\/220: diagnostic potential of O-glycopeptide microarrays. Glycoconj J. 2013;30:633\u201340.","journal-title":"Glycoconj J"},{"key":"3423_CR55","doi-asserted-by":"publisher","first-page":"20577","DOI":"10.1038\/srep20577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Ye X, Jia J, Zhu R, Wang L, Chen C, Yang L, Wang Y, Wang W, Ye J, et al. Serological evaluation of immunity to the Varicella-Zoster virus based on a novel competitive Enzyme-Linked immunosorbent assay. Sci Rep. 2016;6:20577.","journal-title":"Sci Rep"},{"key":"3423_CR56","doi-asserted-by":"crossref","unstructured":"Xue W, Li T, Zhang S, Wang Y, Hong M, Cui L, Wang H, Zhang Y, Chen T, Zhu R et al. Baculovirus display of Varicella-Zoster virus glycoprotein E induces robust humoral and cellular immune responses in mice. Viruses 2022, 14.","DOI":"10.3390\/v14081785"},{"key":"3423_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jviromet.2014.01.014","volume":"200","author":"L Chen","year":"2014","unstructured":"Chen L, Liu J, Wang W, Ye J, Wen L, Zhao Q, Zhu H, Cheng T, Xia N. Development of a varicella-zoster virus neutralization assay using a glycoprotein K antibody enzyme-linked immunosorbent spot assay. J Virol Methods. 2014;200:10\u20134.","journal-title":"J Virol Methods"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03423-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03423-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03423-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:03:32Z","timestamp":1748577812000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03423-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3423"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03423-w","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.L., S.L., S.Z., Y.Z., L.C., Y.G., T.C. and N.X. are inventors on a patent application (PCT\/CN2024\/073289) filed by the Xiamen University that covers gEgI fusion protein design described in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"395"}}